Ion channel diseases in children: Manifestations and management

Current Opinion in Cardiology

Volumn 23, Issue 3, 2008, Pages 184-191

  Schwartz, Peter J ^a,b,c,d,e   Crotti, Lia ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^c STELLENBOSCH UNIVERSITY   (South Africa)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Catecholaminergic polymorphic ventricular tachycardia; Genetic diseases; Implantable cardioverter defibrillation; Long QT syndrome; Sudden death

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; MEXILETINE; NADOLOL; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; PROPRANOLOL; QUINIDINE;

BRUGADA SYNDROME; CALCIUM TRANSPORT; CARDIAC CHANNELOPATHY; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; CHILDHOOD DISEASE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DEFIBRILLATOR; ELECTROCARDIOGRAM; GENETIC ASSOCIATION; HEART DENERVATION; HUMAN; LEFT HEART SYMPATHETIC DENERVATION; LONG QT SYNDROME; PATIENT COMPLIANCE; POTASSIUM CHANNELOPATHY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SHORT QT SYNDROME; SODIUM CHANNELOPATHY; SUDDEN INFANT DEATH SYNDROME;

ARRHYTHMIAS, CARDIAC; BRUGADA SYNDROME; CALCIUM CHANNELS; CHANNELOPATHIES; DEFIBRILLATORS, IMPLANTABLE; GENE THERAPY; HUMANS; ION CHANNELS; LONG QT SYNDROME; POTASSIUM CHANNELS; PREVALENCE; SODIUM CHANNELS;

EID: 41749086869     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e3282fcc2e3     Document Type: Review

References (42)

1. Schwartz PJ, Crotti L. Long QT and short QT syndromes. In: Zipes DP and Jalife J, editors. Cardiac electrophysiology. From cell to bedside. 5th ed. Elsevier, Philadelphia, Pennsylvania, USA. (in press). The most updated review on the subject.
2. Schwartz PJ, Spazzolini C, Crotti L, et al. The Jervell and Lange-Nielsen Syndrome. Natural history, molecular basis, and clinical outcome. Circulation 2006; 113:783-790.
3. v1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 2004; 119:19-31.
4. Priori SG, Napolitano C, Schwartz PJ. Genetics of cardiac arrhythmias. In: Libby P, Bonow RO, Mann DL, Zipes DP, editors. Braunwald's heart disease, 8th ed. Philadelphia, PA: Saunders Elsevier; 2008. pp. 101-109. A recent comprehensive review.
5. Stramba-Badiale M, Crotti L, Goulene K, et al. Electrocardiographic and genetic screening for long QT syndrome: results from a prospective study on 44 596 neonates. Circulation 2007; 116 (Abstr Suppl):II_377.
6. Schwartz PJ, Garson A Jr, Paul T, et al. Guidelines for the interpretation of the neonatal electrocardiogram. Eur Heart J 2002; 23:1329-1344.
7. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003; 348:1866-1874.
8. Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 2001; 103:89-95.
9. Malfatto G, Beria G, Sala S, et al. Quantitative analysis of T wave abnormalities and their prognostic implications in the idiopathic long QT syndrome. J Am Coll Cardiol 1994; 23:296-301.
10. Schwartz PJ. Idiopathic long QT syndrome: progress and questions. Am Heart J 1985; 109:399-411.
11. Schwartz PJ, Moss AJ, Vincent GM, Crampton RS. Diagnostic criteria for the long QT syndrome: an update. Circulation 1993; 88:782-784.
12. Schwartz PJ. The congenital long QT syndromes from genotype to phenotype: clinical implications. J Intern Med 2006; 259:39-47.
13. Probst V, Denjoy I, Meregalli PG, et al. Clinical aspects and prognosis of Brugada syndrome in children. Circulation 2007; 115:2042-2048.
14. Moss AJ, Zareba W, Hall WJ, et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation 2000; 101:616-623.
15. Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA 2004; 292:1341-1344.
16. Schwartz PJ, Priori SG, Cerrone M, et al. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long QT syndrome. Circulation 2004; 109:1826-1833.
17. Zareba W, Moss AJ, Daubert JP, et al. Implantable cardioverter defibrillator in high-risk long QT syndrome patients. J Cardiovasc Electrophysiol 2003; 14:337-341.
18. Crotti L, Spazzolini C, De Ferrari GM, et al. Is the implantable defibrillator appropriately used in the long QT syndrome? Data from the European Registry. Heart Rhythm 2004; 1 (Suppl):582.
19. Wolf MJ, Zeltser IJ, Salerno J, et al. Electrical storm in children with an implantable cardioverter defibrillator: clinical features and outcome. Heart Rhythm 2007; 4 (Suppl):S43.
20. Moss AJ, Shimizu W, Wilde AA, et al. Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulation 2007; 115:2481-2489.
21. Crotti L, Spazzolini C, Schwartz PJ, et al. The common Long QT Syndrome mutation KCNQ1/A341V causes unusually severe clinical manifestations in patients with different ethnic backgrounds: toward a mutation-specific risk stratification. Circulation 2007; 116:2366-2375. This in-depth study of a common mutation has impact on risk stratification and questions the current extrapolations from cellular studies to clinical manifestations.
22. Schwartz PJ, Vanoli E, Crotti L, et al. Neural control of heart rate modifies arrhythmia risk in congenital long QT syndrome. J Am Coll Cardiol 2008; 51:920-929. The first evidence that the autonomic nervous system, probably on a genetic basis, plays the role of 'modifier' of the clinical severity for LQT1 patients.
23. + channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation 1995; 92:3381-3386.
24. Wang DW, Crotti L, Ferrandi C, et al. Highly malignant perinatal variant of long-QT syndrome caused by a profoundly dysfunctional SCN5A mutation successfully treated with mexiletine and propranolol. Circulation 2007; 116 (Abstr Suppl):II_54-II_55.
25. Rosso R, Kalman JM, Rogowski O, et al. Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 2007; 4:1149-1154.
26. Napolitano C, Priori SG. Diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 2007; 4:675-678.
27. Mohamed U, Gollob MH, Gow RM, Krahn AD. Sudden cardiac death despite an implantable cardioverter-defibrillator in a young female with catecholaminergic ventricular tachycardia. Heart Rhythm 2006; 3:1486-1489.
28. Robinson MR, Park J, Raff G. Novel palliative therapy for drug-refractory catecholaminergic polymorphic ventricular tachycardia in a young patient: cardiac autotransplantation followed by orthotopic transplantation. Heart Rhythm 2007; 4 (Suppl):S101.
29. Wilde AAM, Bhuiyan ZA, Crotti L, et al. Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia. N Engl J Med (in press). A novel therapeutic option for high-risk patients with CPVT.
30. Schwartz PJ. Cardiac sympathetic innervation and the sudden infant death syndrome. A possible pathogenetic link. Am J Med 1976; 60:167-172.
31. Schwartz PJ, Priori SG, Dumaine R, et al. A molecular link between the sudden infant death syndrome and the long QT syndrome. N Engl J Med 2000; 343:262-267.
32. Schwartz PJ, Priori SG, Bloise R, et al. Molecular diagnosis in a child with sudden infant death syndrome. Lancet 2001; 358:1342-1343.
33. Tester DJ, Ackerman MJ. Sudden infant death syndrome: how significant are the cardiac channelopathies? Cardiovasc Res 2005; 67:388-396.
34. Arnestad M, Crotti L, Rognum TO, et al. Prevalence of long QT syndrome gene variants in sudden infant death syndrome. Circulation 2007; 115:361-367. The conclusive evidence that LQTS disease-causing mutations contribute significantly to SIDS.
35. Wang DW, Desai RR, Crotti L, et al. Cardiac sodium channel dysfunction in sudden infant death syndrome. Circulation 2007; 115:368-376.
36. Rhodes TE, Abraham RA, Crotti L, et al. Cardiac potassium channel dysfunction in sudden infant death syndrome. J Mol Cell Cardiol 2008; 44:571-581.
37. Schwartz PJ. Newborn ECG screening to prevent sudden cardiac death. Heart Rhythm 2006; 11:1353-1355.
38. Quaglini S, Rognoni C, Spazzolini C, et al. Cost-effectiveness of neonatal ECG screening for the Long QT-Syndrome. Eur Heart J 2006; 15:1824-1832.
39. Schwartz PJ. Stillbirths, sudden infant deaths, and long QT syndrome. Puzzle or mosaic, the pieces of the jigsaw are being fitted together. Circulation 2004; 109:2930-2932.
40. Crotti L, Insolia R, Ghidoni A, et al. Long QT Syndrome as a cause of stillbirths. Circulation 2007; 116 (Abstr Suppl):II_653.
41. Tester DJ, Dura M, Carturan E, et al. A mechanism for sudden infant death syndrome (SIDS): stress-induced leak via ryanodine receptors. Heart Rhythm 2007; 4:733-739.
42. Van Norstrand DW, Valdivia CR, Tester DJ, et al. Molecular and functional characterization of novel glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) mutations in sudden infant death syndrome. Circulation 2007; 116:2253-2259.